<DOC>
	<DOCNO>NCT00111462</DOCNO>
	<brief_summary>The purpose study compare effect darbepoetin alfa administer weight base versus fix dose treatment anemia subject non-myeloid malignancy receive multicycle chemotherapy .</brief_summary>
	<brief_title>Evaluating Treatment Anemia Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Planned chemotherapy treatment Anemia ( hemoglobin concentration less equal 11.0 g/dL ) Adequate renal liver function Eastern Cooperative Oncology Group ( ECOG ) 0 2 Subjects must provide write informed consent Exclusion Criteria : Known history seizure disorder Known primary hematologic disorder cause anemia nonmyeloid malignancy Unstable/uncontrolled cardiac condition Clinically significant inflammatory disease Known positive test HIV infection Transfusion within 4 week randomization Neutralizing antibodies erythropoietic agent Treatment erythropoietic therapy within 4 week randomization Received investigational drug device within 30 day randomization Pregnant breast feed Not use adequate contraceptive precaution Previously randomize study Known hypersensitivity product administer Concerns subject 's compliance</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>non-myeloid malignancy</keyword>
	<keyword>chemotherapy-induced anemia</keyword>
</DOC>